ICON plc/ICLR

$314.19

0.26%
-
1D1W1MYTD1YMAX

About ICON plc

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Ticker
ICLR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Stephen Cutler
Employees
41,150
Headquarters
Dublin, Ireland

ICON plc Metrics

BasicAdvanced
$25.92B
Market cap
42.53
P/E ratio
$7.39
EPS
1.14
Beta
-
Dividend rate

What the Analysts think about ICON plc

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 13 analysts.
11.4% upside
High $385.00
Low $285.00
$314.19
Current price
$350.00
Average price target

ICON plc Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
10.47% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.07B
0.55%
Net income
$216.4M
32.27%
Profit margin
10.47%
31.53%

ICON plc Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.64%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
$2.90
$3.11
$3.30
-
Expected
$2.88
$3.08
$3.28
$3.46
Surprise
0.86%
1.11%
0.64%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ICON plc stock

Buy or sell ICON plc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing